# HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

> **NCT01023620** · NA · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 4 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Pioglitazone
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT01023620
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-05-31
- **Final completion:** 2010-05-31
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2019-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01023620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01023620, "HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01023620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*